Switching inhaled iloprost formulations in patients with pulmonary arterial hypertension: the VENTASWITCH Trial

Autor: Manuel J. Richter, Barbara Stollfuß, Alexander Roitenberg, Frank Kleinjung, Valentin Graeff, Sabine Berghaus, Christian Müller, Hossein-Ardeschir Ghofrani
Jazyk: angličtina
Rok vydání: 2018
Předmět:
Zdroj: Pulmonary Circulation, Vol 8 (2018)
Druh dokumentu: article
ISSN: 2045-8940
20458940
94815674
DOI: 10.1177/2045894018798921
Popis: Inhaled iloprost is an effective therapy for patients with pulmonary arterial hypertension (PAH); however, some patients experience extended inhalation times when using the V10 formulation (10.0 µg/mL) to deliver a 5 -µg dose (at mouthpiece) and are at risk of incomplete inhalations and reduced inhalation frequency. VENTASWITCH was an observational, case-crossover study to evaluate inhalation behavior in patients with PAH switched from iloprost V10 to V20 (20.0 µg/mL) formulation for delivering a 5 -µg dose using the I-Neb® AAD® device. Adults with PAH participating in a German Ventavis® (iloprost) patient-support program, who were switched from the V10 to V20 formulation, were enrolled. The co-primary endpoints were mean daily proportion of complete inhalations and mean daily inhalation frequency. The secondary endpoint was mean daily inhalation duration. Data were collected for three months before and after switching. Overall, 63 patients were included. Switching from V10 to V20 resulted in a significant increase in the mean daily proportion of complete inhalations (92% vs. 97%, P
Databáze: Directory of Open Access Journals
Externí odkaz: